175 related articles for article (PubMed ID: 35111018)
1. Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
Lanman T; Hayden Gephart M; Bui N; Toland A; Nagpal S
Case Rep Oncol; 2021; 14(3):1841-1846. PubMed ID: 35111018
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
3. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report.
Palmerini E; Frega G; Gambarotti M; Frisoni T; Cesari M; Bazzocchi A; Miceli M; Donati DM; Fanti S; Nanni C; Benini S; Longhi A; Paioli A; Marrari A; Hakim R; Righi A; Ibrahim T
Front Oncol; 2023; 13():1252359. PubMed ID: 37876963
[TBL] [Abstract][Full Text] [Related]
4. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
5. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
Wu WC; Chen MH
Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
[TBL] [Abstract][Full Text] [Related]
7. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
[No Abstract] [Full Text] [Related]
8. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract][Full Text] [Related]
9. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Frampton JE
Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
[TBL] [Abstract][Full Text] [Related]
10. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
12. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.
Liu F; Wei Y; Zhang H; Jiang J; Zhang P; Chu Q
Front Oncol; 2022; 12():864666. PubMed ID: 35372074
[TBL] [Abstract][Full Text] [Related]
13. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
[TBL] [Abstract][Full Text] [Related]
14. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
Laetsch TW; Hong DS
Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
[TBL] [Abstract][Full Text] [Related]
15. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
16. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
[TBL] [Abstract][Full Text] [Related]
17. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
[TBL] [Abstract][Full Text] [Related]
18. How selecting best therapy for metastatic
Ekman S
Transl Lung Cancer Res; 2020 Dec; 9(6):2535-2544. PubMed ID: 33489816
[TBL] [Abstract][Full Text] [Related]
19. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
20. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]